Ascendant Labs

Ascendant Labs is a biotechnology company established in 2023 as a joint venture between Absci Corporation and Eikon Therapeutics. The company integrates Absci's generative AI-powered Integrated Drug Creation platform with Eikon's proprietary live-cell super-resolution microscopy and engineering technologies. This synergy is designed to identify and drug high-value targets that were previously considered intractable. Ascendant Labs focuses on the de novo design of antibodies and other biologics to address significant unmet medical needs across various therapeutic areas. By combining real-time cellular imaging with high-throughput AI drug design, the company aims to significantly accelerate the path from target identification to clinical candidates.